AZD6621 / AstraZeneca - LARVOL DELTA

AZD6621: Improving the therapeutic index for prostate cancer T cell engagers with a next-generation CD8-guided format (AACR 2025) - "Furthermore, when matched for anti-tumor activity in an intravenous 22Rv1 xenograft model, systemic cytokine levels were significantly reduced in AZD6621-treated mice compared to a conventional TCE. These data provide reason to believe that AZD6621 can improve the therapeutic index of conventional TCEs via CD8-guided, affinity-optimized CD3 engagement of STEAP2 on prostate cancer cells and support a first-in-human clinical trial planned to start in 2025."

Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CD4 • CD8 • STEAP1 • STEAP2